Drugs / BNT162b2 OMI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04955626 | Jul 2021 → May 2023 | COVID-19 | BioNTech SE | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT162b2 OMI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04955626 ↗ |
| Modality | Messenger RNA (mRNA) | “adults 18‒55 years old who had previously received three 30 μg doses of BNT162b2 vaccine were randomized to receive a 60 or 30 μg dose of bivalent Omicron BA.1‒adapted BNT162b2...” PMID 41560517 ↗ May 2026 |